Stomach cancer explained

Stomach cancer
Synonyms:Gastric cancer
Field:Gastroenterology Oncology
Symptoms:Early: Later:
Onset:Over years
Types:Gastric carcinomas, lymphoma, mesenchymal tumor
Causes:Helicobacter pylori, genetics
Risks:Smoking, dietary factors such as pickled vegetables, obesity
Diagnosis:Biopsy done during endoscopy
Prevention:Mediterranean diet, not smoking
Treatment:Surgery, chemotherapy, radiation therapy, targeted therapy
Prognosis:Five-year survival rate


< 10% (advanced cases),
32% (US), 71% (Japan)

Frequency:968,350 (2022)[1]
Deaths:659,853 (2022)

Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.[2] Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. Lymphomas and mesenchymal tumors may also develop in the stomach. Early symptoms may include heartburn, upper abdominal pain, nausea, and loss of appetite. Later signs and symptoms may include weight loss, yellowing of the skin and whites of the eyes, vomiting, difficulty swallowing, and blood in the stool, among others.[3] The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen, and lymph nodes.[4]

The most common cause is infection by the bacterium Helicobacter pylori, which accounts for more than 60% of cases.[5] [6] Certain strains of H. pylori have greater risks than others. Smoking, dietary factors such as pickled vegetables and obesity are other risk factors.[7] About 10% of cases run in families, and between 1% and 3% of cases are due to genetic syndromes inherited such as hereditary diffuse gastric cancer. Most of the time, stomach cancer develops in stages over years. Diagnosis is usually by biopsy done during endoscopy.[3] This is followed by medical imaging to determine if the disease has spread to other parts of the body.[3] Japan and South Korea, two countries that have high rates of the disease, screen for stomach cancer.

A Mediterranean diet lowers the risk of stomach cancer, as does not smoking. Tentative evidence indicates that treating H. pylori decreases the future risk.[8] If stomach cancer is treated early, it can be cured. Treatments may include some combination of surgery, chemotherapy, radiation therapy, and targeted therapy.[3] [9] For certain subtypes of gastric cancer, cancer immunotherapy is an option as well.[10] If treated late, palliative care may be advised. Some types of lymphoma can be cured by eliminating H. pylori.[11] Outcomes are often poor, with a less than 10% five-year survival rate in the Western world for advanced cases. This is largely because most people with the condition present with advanced disease.[12] In the United States, five-year survival is 31.5%,[13] while in South Korea it is over 65% and Japan over 70%, partly due to screening efforts.[14]

Globally, stomach cancer is the fifth-leading type of cancer and the third-leading cause of death from cancer, making up 7% of cases and 9% of deaths.[15] In 2018, it newly occurred in 1.03 million people and caused 783,000 deaths.[16] Before the 1930s, it was a leading cause of cancer deaths in the Western world, however rates have sharply declined among younger generations in the West, while they remain high for people living in East Asia.[17] [18] [19] The decline in the West is believed to be due to the decline of salted and pickled food consumption, as a result of the development of refrigeration as a method of preserving food.[20] Stomach cancer occurs most commonly in East Asia, followed by Eastern Europe. It occurs twice as often in males as in females.[21]

Signs and symptoms

Stomach cancer is often either asymptomatic (producing no noticeable symptoms) or it may cause only nonspecific symptoms (which may also be present in other related or unrelated disorders) in its early stages. By the time symptoms are recognized, the cancer has often reached an advanced stage (see below) and may have metastasized (spread to other, perhaps distant, parts of the body), which is one of the main reasons for its relatively poor prognosis.[22] Stomach cancer can cause the following signs and symptoms: Unexplained nausea, vomiting, diarrhoea and constipation. Patients also can experience unexplained weight loss.[23]

Early cancers may be associated with indigestion or a burning sensation (heartburn). However, fewer than one in every 50 people referred for endoscopy due to indigestion has cancer.[24] Abdominal discomfort and loss of appetite can occur.[25] [26]

Gastric cancers that have enlarged and invaded normal tissue can cause weakness, fatigue, bloating of the stomach after meals, abdominal pain in the upper abdomen, nausea and occasional vomiting. Further enlargement may cause weight loss or bleeding with vomiting blood or having blood in the stool, the latter apparent as black discolouration (melena) and sometimes leading to anemia. Dysphagia suggests a tumour in the cardia or extension of the gastric tumour into the esophagus.

These can be symptoms of other problems such as a stomach virus, gastric ulcer, or tropical sprue.

Risk factors

Gastric cancer can occur as a result of many factors.[27] It occurs twice as commonly in males as females. Estrogen may protect women against the development of this form of cancer.[28] [29]

Infections

Helicobacter pylori infection is an essential risk factor in 65–80% of gastric cancers, but only 2% of people with H. pylori infections develop stomach cancer.[30] The mechanism by which H. pylori induces stomach cancer potentially involves chronic inflammation, the action of H. pylori virulence factors such as CagA,[31] or an interaction between H. pylori infection and germline pathogenic variants in homologous-recombination genes.[32] It was estimated that Epstein–Barr virus is responsible for 84,000 cases per year.[33] AIDS is also associated with elevated risk.[7]

Smoking

Smoking increases the risk of developing gastric cancer significantly, from 40% increased risk for current smokers to 82% increase for heavy smokers. Gastric cancers due to smoking mostly occur in the upper part of the stomach near the esophagus.[34] [35]

Alcohol

Some studies show increased risk with alcohol consumption as well.[7] [36]

Diet

Dietary factors are not proven causes, and the association between stomach cancer and various foods and beverages is weak.[37] Some foods including fried foods,[38] smoked foods, salt and salt-rich foods, meat,[39] processed meat, red meat, pickled vegetables, and brackens[40] are associated with a higher risk of stomach cancer.[7] [41]

Fresh fruit and vegetable intake,[42] citrus fruit intake, and antioxidant intake are associated with a lower risk of stomach cancer.[7] [43] A Mediterranean diet is associated with lower rates of stomach cancer,[44] as is regular aspirin use.[7]

Obesity is a physical risk factor that has been found to increase the risk of gastric adenocarcinoma by contributing to the development of gastroesophageal reflux disease (GERD).[45] The exact mechanism by which obesity causes GERD is not completely known. Studies hypothesize that increased dietary fat leading to increased pressure on the stomach and the lower esophageal sphincter, due to excess adipose tissue, could play a role, yet no statistically significant data have been collected.[46] However, the risk of gastric cardia adenocarcinoma, with GERD present, has been found to increase more than two times for an obese person.[45] There is a correlation between iodine deficiency and gastric cancer.[47] [48] [49]

Genetics

About 10% of cases run in families, and between 1 and 3% of cases are due to genetic syndromes inherited such as hereditary diffuse gastric cancer.[21]

A genetic risk factor for gastric cancer is a genetic defect of the CDH1 gene known as hereditary diffuse gastric cancer (HDGC). The CDH1 gene, which codes for E-cadherin, lies on the 16th chromosome. When the gene experiences a particular mutation, gastric cancer develops through a mechanism that is not fully understood.[50] [51] This mutation is considered autosomal dominant, meaning that half of a carrier's children will likely experience the same mutation.[50] Diagnosis of hereditary diffuse gastric cancer usually takes place when at least two cases involving a family member, such as a parent or grandparent, are diagnosed, with at least one diagnosed before the age of 50.[50] The diagnosis can also be made if at least three cases occur in the family, in which case age is not considered.[50]

The International Cancer Genome Consortium is leading efforts to identify genomic changes involved in stomach cancer.[52] [53] A very small percentage of diffuse-type gastric cancers (see Histopathology below) arise from an inherited abnormal CDH1 gene. Genetic testing and treatment options are available for families at risk.[54]

Heavy metals

Heavy metals, such as arsenic, are commonly found in groundwater and have been linked to gastric cancers. There is a positive and significant relationship between arsenic concentration in groundwater and gastric cancer mortality.[55]

Other

Other risk factors include diabetes,[56] pernicious anemia,[36] chronic atrophic gastritis,[57] Menetrier's disease (hyperplastic, hypersecretory gastropathy),[58] and intestinal metaplasia.[59]

In addition, Foxp3 polymorphism (rs3761548) might contribute to gastric cancer development through influencing Treg cell activity.[60]

In a human retrospective study, biliary reflux was found to be a likely risk factor for gastric cancer and precancerous lesions.[61]

Diagnosis

To find the cause of symptoms, the doctor asks about the patient's medical history, does a physical examination, and may order laboratory studies.[62] The patient may also have one or all of these exams:

In 2013, Chinese and Israeli scientists reported a successful pilot study of a breathalyzer-style breath test intended to diagnose stomach cancer by analyzing exhaled chemicals without the need for an intrusive endoscopy.[64] [65] A larger-scale clinical trial of this technology was completed in 2014.[66] [67]

Abnormal tissue seen in a gastroscope examination is biopsied by the surgeon or gastroenterologist. This tissue is then sent to a pathologist for histological examination under a microscope to check for the presence of cancerous cells. A biopsy, with subsequent histological analysis, is the only sure way to confirm the presence of cancer cells.[36]

Various gastroscopic modalities have been developed to increase yield of detected mucosa with a dye that accentuates the cell structure and can identify areas of dysplasia. Endocytoscopy involves ultra-high magnification to visualise cellular structure to better determine areas of dysplasia. Other gastroscopic modalities such as optical coherence tomography are being tested investigationally for similar applications.[68]

A number of cutaneous conditions are associated with gastric cancer. A condition of darkened hyperplasia of the skin, frequently of the axilla and groin, known as acanthosis nigricans, is associated with intra-abdominal cancers such as gastric cancer. Other cutaneous manifestations of gastric cancer include "tripe palms" (a similar darkening hyperplasia of the skin of the palms) and the Leser-Trelat sign, which is the rapid development of skin lesions known as seborrheic keratoses.[69]

Various blood tests may be done, including a complete blood count to check for anaemia, and a fecal occult blood test to check for blood in the stool.[70]

Histopathology

Staging

If cancer cells are found in the tissue sample, the next step is to stage, or find out the extent of the disease. Various tests determine whether the cancer has spread, and if so, what parts of the body are affected. Because stomach cancer can spread to the liver, pancreas, and other organs near the stomach, as well as to the lungs, the doctor may order a CT scan, a PET scan,[74] an endoscopic ultrasound exam, or other tests to check these areas. Blood tests for tumor markers, such as carcinoembryonic antigen and carbohydrate antigen may be ordered, as their levels correlate to extent of metastasis, especially to the liver, and the cure rate.

Staging may not be complete until after surgery. The surgeon removes nearby lymph nodes and possibly samples of tissue from other areas in the abdomen for examination by a pathologist.

The clinical stages of stomach cancer are:[75] [76]

The TNM staging system is also used.[77]

In a study of open-access endoscopy in Scotland, patients were diagnosed 7% in stage I, 17% in stage II, and 28% in stage III.[78] A Minnesota population was diagnosed 10% in stage I, 13% in stage II, and 18% in stage III.[79] However, in a high-risk population in the Valdivia Province of southern Chile, only 5% of patients were diagnosed in the first two stages and 10% in stage III.[80]

Prevention

Getting rid of H. pylori in those who are infected decreases the risk of stomach cancer.[81] A 2014 meta-analysis of observational studies found that a diet high in fruits, mushrooms, garlic, soybeans, and green onions was associated with a lower risk of stomach cancer in the Korean population.[82] Low doses of vitamins, especially from a healthy diet, decrease the risk of stomach cancer.[83] A previous review of antioxidant supplementation did not find supporting evidence and possibly worse outcomes.[84] [85] Modern technology is used to promote early diagnosis, e.g. based on serum markers.[86]

Management

Cancer of the stomach is difficult to cure unless it is found at an early stage (before it has begun to spread). Unfortunately, because early stomach cancer causes few symptoms, the disease is usually advanced when the diagnosis is made.[87]

Treatment for stomach cancer may include surgery,[88] chemotherapy, or radiation therapy.[89] New treatment approaches such as immunotherapy or gene therapy and improved ways of using current methods are being studied in clinical trials.[90]

Surgery

Surgery remains the only curative therapy for stomach cancer.[12] A 2016 Cochrane review found low-quality evidence of no difference in short-term mortality between laparoscopic and open gastrectomy (removal of stomach), and that benefits or harms of laparoscopic gastrectomy cannot be ruled out.[91] Post-operatively, up to 70% of people undergoing total gastrectomy develop complications such as dumping syndrome and reflux esophagitis.[92] Construction of a "pouch", which serves as a "stomach substitute", reduced the incidence of dumping syndrome and reflux esophagitis by 73% and 63% respectively, and led to improvements in quality-of-life, nutritional outcomes, and body mass index. Proximal gastrectomy (PG) can be considered a viable alternative for upper third early gastric cancer (EGC)[93] Of the different surgical techniques, endoscopic mucosal resection (EMR) is a treatment for early gastric cancer (tumor only involves the mucosa) that was pioneered in Japan and is available in the United States at some centers.[12] In EMR, the tumor, together with the inner lining of stomach (mucosa), is removed from the wall of the stomach using an electrical wire loop through the endoscope. The advantage is that it is a much smaller operation than removing the stomach.[12] Endoscopic submucosal dissection is a similar technique pioneered in Japan, used to resect a large area of mucosa in one piece.[12] If the pathologic examination of the resected specimen shows incomplete resection or deep invasion by tumor, the patient would need a formal stomach resection.[12]

Those with metastatic disease at the time of presentation may receive palliative surgery, and while it remains controversial, due to the possibility of complications from the surgery itself and because it may delay chemotherapy, the data so far are mostly positive, with improved survival rates being seen in those treated with this approach.[12] [94]

Chemotherapy

The use of chemotherapy to treat stomach cancer has no firmly established standard of care. Unfortunately, stomach cancer has not been particularly sensitive to these drugs, and chemotherapy, if used, has usually served to palliatively reduce the size of the tumor, relieve symptoms of the disease, and increase survival time. Some drugs used in stomach cancer treatment have included: fluorouracil or its analog capecitabine, BCNU (carmustine), methyl-CCNU (semustine) and doxorubicin (Adriamycin), as well as mitomycin C, and more recently cisplatin and taxotere, often using drugs in various combinations.[9] The relative benefits of these different drugs, alone and in combination, are unclear.[95] Clinical researchers are exploring the benefits of giving chemotherapy before surgery to shrink the tumor, or as adjuvant therapy after surgery to destroy remaining cancer cells.[12]

Targeted therapy

Recently, treatment with human epidermal growth factor receptor 2 (HER2) inhibitor, trastuzumab, has been demonstrated to increase overall survival in inoperable locally advanced or metastatic gastric carcinoma over-expressing the HER2/neu gene. In particular, HER2 is overexpressed in 13–22% of patients with gastric cancer.[96] Of note, HER2 overexpression in gastric neoplasia is heterogeneous and comprises a minority of tumor cells (less than 10% of gastric cancers overexpress HER2 in more than 5% of tumor cells). Hence, this heterogeneous expression should be taken into account for HER2 testing, particularly in small samples such as biopsies, requiring the evaluation of more than one bioptic sample.

Radiation

Radiation therapy (also called radiotherapy) may be used to treat stomach cancer, often as an adjuvant to chemotherapy and/or surgery.[12]

Lymphoma

MALT lymphomas are often completely resolved after the underlying H. pylori infection is treated.[11] This results in remission in about 80% of cases.[11]

Prognosis

The prognosis of stomach cancer is generally poor, because the tumor has often metastasized by the time of discovery, and most people with the condition are elderly (median age is between 70 and 75 years) at presentation. The average life expectancy after being diagnosed is around 24 months, and the five-year survival rate for stomach cancer is less than 10%.[12]

Almost 300 genes are related to outcomes in stomach cancer, with both unfavorable genes where high expression is related to poor survival and favorable genes where high expression is associated with longer survival times.[97] [98] Examples of poor prognosis genes include ITGAV, DUSP1 and P2RX7.[99]

Epidemiology

In 2018, stomach cancer was the fifth most frequently diagnosed cancer worldwide, representing 5.7% of all cancer cases, and the third leading cause of death from cancers, being responsible for 8.2% of all cancer deaths.[100] Among men, 683 754 cases were diagnosed, accounting for 7.2% of all cancer cases, and among women, stomach cancer was diagnosed in 349 947 cases, accounting for 4.1% of all cancer cases.

In 2012, stomach cancer was the fifth most-common cancer with 952,000 cases diagnosed. It is more common both in men and in developing countries.[101] [102] In 2012, it represented 8.5% of cancer cases in men, making it the fourth most-common cancer in men.[103] Also in 2012, the number of deaths was 700,000, having decreased slightly from 774,000 in 1990, making it the third-leading cause of cancer-related death (after lung cancer and liver cancer).[104] [105]

Less than 5% of stomach cancers occur in people under 40 years of age, with 81.1% of that 5% in the age-group of 30 to 39 and 18.9% in the age-group of 20 to 29.[106]

In 2014, stomach cancer resulted in 0.61% of deaths (13,303 cases) in the United States.[107] In China, stomach cancer accounted for 3.56% of all deaths (324,439 cases).[108] The highest rate of stomach cancer was in Mongolia, at 28 cases per 100,000 people.[109]

In the United Kingdom, stomach cancer is the 15th most-common cancer (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the 10th most-common cause of cancer-related deaths (around 4,800 people died in 2012).[110]

Incidence and mortality rates of gastric cancer vary greatly in Africa. The GLOBOCAN system is currently the most widely used method to compare these rates between countries, but African incidence and mortality rates are seen to differ among countries, possibly due to the lack of universal access to a registry system for all countries.[111] Variation as drastic as estimated rates from 0.3/100000 in Botswana to 20.3/100000 in Mali have been observed.[111] In Uganda, the incidence of gastric cancer has increased from the 1960s measurement of 0.8/100000 to 5.6/100000.[111] Gastric cancer, though present, is relatively low when compared to countries with high incidence like Japan and China. One suspected cause of the variation within Africa and between other countries is due to different strains of the H. pylori bacteria. The trend commonly seen is that H. pylori infection increases the risk for gastric cancer, but this is not the case in Africa, giving this phenomenon the name the "African enigma".[112] Although this bacterial species is found in Africa, evidence has supported that different strains with mutations in the bacterial genotype may contribute to the difference in cancer development between African countries and others outside the continent.[112] Increasing access to health care and treatment measures have been commonly associated with the rising incidence, though, particularly in Uganda.[111]

Other animals

The stomach is a muscular organ of the gastrointestinal tract that holds food and begins the digestive process by secreting gastric juice. The most common cancers of the stomach are adenocarcinomas, but other histological types have been reported. Signs vary, but may include vomiting (especially if blood is present), weight loss, anemia, and lack of appetite. Bowel movements may be dark and tarry in nature. To determine whether cancer is present in the stomach, special X-rays and/or abdominal ultrasounds may be performed. Gastroscopy, a test using an endoscope to examine the stomach, is a useful diagnostic tool that can also take samples of the suspected mass for histopathological analysis to confirm or rule out cancer. The most definitive method of cancer diagnosis is through open surgical biopsy.[113] Most stomach tumors are malignant with evidence of spread to lymph nodes or liver, making treatment difficult. Except for lymphoma, surgery is the most frequent treatment option for stomach cancers but it is associated with significant risks.

A carcinogenic interaction was demonstrated between bile acids and Helicobacter pylori in a mouse model of gastric cancer.[114] [115]

External links

Notes and References

  1. Bray . Freddie . Laversanne . Mathieu . Sung . Hyuna . Ferlay . Jacques . Siegel . Rebecca L. . Soerjomataram . Isabelle . Jemal . Ahmedin . 2024-04-04 . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA: A Cancer Journal for Clinicians . 74 . 3 . 229–263 . en . 10.3322/caac.21834 . 0007-9235. free . 38572751 .
  2. Web site: Stomach (Gastric) Cancer. NCI. 1 July 2014. live. https://web.archive.org/web/20140704181619/http://www.cancer.gov/cancertopics/types/stomach. 4 July 2014. January 1980.
  3. Web site: Gastric Cancer Treatment (PDQ®). NCI. 1 July 2014. 17 April 2014. live. https://web.archive.org/web/20140705231337/http://www.cancer.gov/cancertopics/pdq/treatment/gastric/Patient/page1/AllPages. 5 July 2014.
  4. Book: Ruddon RW . Cancer biology. 2007. Oxford University Press. 978-0-19-517543-1. 223. 4th. live. https://web.archive.org/web/20150915231411/https://books.google.com/books?id=PymZ1ORk0TcC&pg=PA223. 15 September 2015.
  5. . Role of bacteria in oncogenesis . Clinical Microbiology Reviews . 23 . 4 . 837–857 . October 2010 . 20930075 . 2952975 . 10.1128/CMR.00012-10 .
  6. Book: Sim F, McKee M . Issues in public health . 2011 . Open University Press . 978-0-335-24422-5 . 74 . 2nd.
  7. González CA, Sala N, Rokkas T . Gastric cancer: epidemiologic aspects . Helicobacter . 18 . Suppl 1 . 34–38 . September 2013 . 24011243 . 10.1111/hel.12082 . 22918077 . free .
  8. Web site: Stomach (Gastric) Cancer Prevention (PDQ®). NCI. 1 July 2014. 27 February 2014. live. https://web.archive.org/web/20140704195947/http://www.cancer.gov/cancertopics/pdq/prevention/gastric/HealthProfessional. 4 July 2014.
  9. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S . Chemotherapy for advanced gastric cancer . The Cochrane Database of Systematic Reviews . 2017 . CD004064 . August 2017 . 8 . 28850174 . 6483552 . 10.1002/14651858.cd004064.pub4 .
  10. Kodach LL, Peppelenbosch MP . Targeting the Myeloid-Derived Suppressor Cell Compartment for Inducing Responsiveness to Immune Checkpoint Blockade Is Best Limited to Specific Subtypes of Gastric Cancers . Gastroenterology . 161 . 2 . 727 . August 2021 . 33798523 . 10.1053/j.gastro.2021.03.047 . free .
  11. Stathis A, Bertoni F, Zucca E . Treatment of gastric marginal zone lymphoma of MALT type . Expert Opinion on Pharmacotherapy . 11 . 13 . 2141–2152 . September 2010 . 20586708 . 10.1517/14656566.2010.497141 . 6796557 .
  12. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F . Treatment of gastric cancer . World Journal of Gastroenterology . 20 . 7 . 1635–1649 . February 2014 . 24587643 . 3930964 . 10.3748/wjg.v20.i7.1635 . dmy-all . free .
  13. Web site: Cancer of the Stomach - Cancer Stat Facts. SEER. en. 1 February 2020.
  14. Web site: がん診療連携拠点病院等院内がん登録生存率集計: [国立がん研究センター がん登録・統計] ]. ganjoho.jp . 2 February 2020.
  15. Book: Stewart BW, Wild C . International Agency for Research on Cancer . World Health Organization. World Cancer Report 2014. 2014. World Health Organization. 978-92-832-0429-9. 1.1 The global and regional burden of cancer . .
  16. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA: A Cancer Journal for Clinicians. 68 . 6 . 394–424 . November 2018 . 30207593 . 10.3322/caac.21492 . 52188256 . free .
  17. Book: Tobias SJ, Hochhauser D, Souhami RL . Cancer and its management. 2010. Wiley-Blackwell. 978-1-4443-0637-8. 259. 6th.
  18. Book: Khleif RT, Skeel SN . Handbook of cancer chemotherapy. 2011. Wolter Kluwer. 978-1-60831-782-0. 127. 8th.
  19. Book: Knight JA . Human Longevity: The Major Determining Factors. 2010. Author House. 978-1-4520-6722-3. 339. live. https://web.archive.org/web/20150916003533/https://books.google.com/books?id=HBY_GxOY_6oC&pg=PA339. 16 September 2015.
  20. Book: Moore RJ, Spiegel D . Cancer, culture, and communication. 2004. Kluwer Academic. 978-0-306-47885-7. 139.
  21. Book: . 2014. 5.4 Stomach Cancer.
  22. Web site: Statistics and outlook for stomach cancer. Cancer Research UK. 19 February 2014. live. https://web.archive.org/web/20140105105505/http://www.cancerresearchuk.org/cancer-help/type/stomach-cancer/treatment/statistics-and-outlook-for-stomach-cancer. 5 January 2014.
  23. Al-Azri M, Al-Kindi J, Al-Harthi T, Al-Dahri M, Panchatcharam SM, Al-Maniri A . Awareness of Stomach and Colorectal Cancer Risk Factors, Symptoms and Time Taken to Seek Medical Help Among Public Attending Primary Care Setting in Muscat Governorate, Oman . Journal of Cancer Education . 34 . 3 . 423–434 . June 2019 . 28782080 . 10.1007/s13187-017-1266-8 . 4017466 .
  24. Web site: Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers . NHS . Jan 2001 . dead . https://web.archive.org/web/20121013060159/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4080278.pdf . 13 October 2012 .
  25. Web site: Symptoms of stomach cancer. 17 September 2018. nhs.uk.
  26. Ehret C, Jatoi A . Should Loss of Appetite Be Palliated in Patients with Advanced Cancer? . Current Treatment Options in Oncology . 22 . 4 . 31 . February 2021 . 33641020 . 7914034 . 10.1007/s11864-021-00829-0 .
  27. Lee YY, Derakhshan MH . Environmental and lifestyle risk factors of gastric cancer . Archives of Iranian Medicine . 16 . 6 . 358–365 . June 2013 . 23725070 . . 3 May 2019 . dead . https://web.archive.org/web/20200918232240/http://www.ams.ac.ir/AIM/NEWPUB/13/16/6/0010.pdf . 18 September 2020 .
  28. Chandanos E, Lagergren J . Oestrogen and the enigmatic male predominance of gastric cancer . European Journal of Cancer . 44 . 16 . 2397–2403 . November 2008 . 18755583 . 10.1016/j.ejca.2008.07.031 .
  29. Qin J, Liu M, Ding Q, Ji X, Hao Y, Wu X, Xiong J . The direct effect of estrogen on cell viability and apoptosis in human gastric cancer cells . Molecular and Cellular Biochemistry . 395 . 1–2 . 99–107 . October 2014 . 24934239 . 10.1007/s11010-014-2115-2 . 14288660 .
  30. Web site: Proceedings of the fourth Global Vaccine Research Forum . April 2004 . Initiative for Vaccine Research team of the Department of Immunization, Vaccines and Biologicals . WHO . Epidemiology of Helicobacter pylori and gastric cancer... . 11 May 2009 . dead . https://web.archive.org/web/20090727175108/http://www.who.int/vaccine_research/documents/en/gvrf2003.pdf . 27 July 2009 .
  31. Hatakeyama M, Higashi H . Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis . Cancer Science . 96 . 12 . 835–843 . December 2005 . 16367902 . 10.1111/j.1349-7006.2005.00130.x . 5721063 . free . 11159386 .
  32. Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, Ito H, Imoto I, Tanaka T, Tajika M, Niwa Y, Iwasaki Y, Aoi T, Hakozaki N, Takata S, Suzuki K, Terao C, Hatakeyama M, Hirata M, Sugano K, Yoshida T, Kamatani Y, Nakagawa H, Matsuda K, Murakami Y, Spurdle AB, Matsuo K, Momozawa Y . Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer . The New England Journal of Medicine . 388 . 13 . 1181–1190 . March 2023 . 36988593 . 10.1056/NEJMoa2211807 . 257804097 .
  33. Web site: Developing a vaccine for the Epstein–Barr Virus could prevent up to 200,000 cancers globally say experts . Cancer Research UK . 24 March 2014. 17 March 2017 . live . https://web.archive.org/web/20170319073808/http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2014-03-24-developing-a-vaccine-for-the-epstein-barr-virus-could-prevent-up-to-200000-cancers-globally-say . 19 March 2017 .
  34. Nomura A, Grove JS, Stemmermann GN, Severson RK . Cigarette smoking and stomach cancer . Cancer Research . 50 . 21 . 7084 . November 1990 . 2208177 .
  35. Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A . Tobacco smoking and gastric cancer: review and meta-analysis . International Journal of Cancer . 72 . 4 . 565–573 . August 1997 . 9259392 . 10.1002/(SICI)1097-0215(19970807)72:4<565::AID-IJC3>3.0.CO;2-O . 42758668 . free .
  36. Thrumurthy SG, Chaudry MA, Hochhauser D, Mughal M . The diagnosis and management of gastric cancer . BMJ . 347 . 16 . f6367 . November 2013 . 24191271 . 10.1136/bmj.f6367 . 16351105 .
  37. Theodoratou E, Timofeeva M, Li X, Meng X, Ioannidis JP . Nature, Nurture, and Cancer Risks: Genetic and Nutritional Contributions to Cancer . Annual Review of Nutrition . 37 . 293–320 . August 2017 . 28826375 . 6143166 . 10.1146/annurev-nutr-071715-051004 . Review .
  38. Zhang T, Song SS, Liu M, Park S . Association of Fried Food Intake with Gastric Cancer Risk: A Systemic Review and Meta-Analysis of Case-Control Studies . Nutrients . 15 . 13 . June 2023 . 2982 . 37447308 . 10347084 . 10.3390/nu15132982 . free .
  39. Ferro A, Rosato V, Rota M, Costa AR, Morais S, Pelucchi C, Johnson KC, Hu J, Palli D, Ferraroni M, Zhang ZF, Bonzi R, Yu GP, Peleteiro B, López-Carrillo L, Tsugane S, Hamada GS, Hidaka A, Zaridze D, Maximovitch D, Vioque J, Navarrete-Munoz EM, Aragonés N, Martín V, Hernández-Ramírez RU, Bertuccio P, Ward MH, Malekzadeh R, Pourfarzi F, Mu L, López-Cervantes M, Persiani R, Kurtz RC, Lagiou A, Lagiou P, Boffetta P, Boccia S, Negri E, Camargo MC, Curado MP, La Vecchia C, Lunet N . Meat intake and risk of gastric cancer in the Stomach cancer Pooling (StoP) project . Int J Cancer . 147 . 1 . 45–55 . July 2020 . 31584199 . 8550819 . 10.1002/ijc.32707 .
  40. Alonso-Amelot ME, Avendaño M . Human carcinogenesis and bracken fern: a review of the evidence . Current Medicinal Chemistry . 9 . 6 . 675–686 . March 2002 . 11945131 . 10.2174/0929867023370743 . dead . dmy-all . https://web.archive.org/web/20111006102621/http://www.benthamdirect.org/pages/content.php?CMC%2F2002%2F00000009%2F00000006%2F0004C.SGM . 6 October 2011 .
  41. Jakszyn P, Gonzalez CA . Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence . World Journal of Gastroenterology . 12 . 27 . 4296–4303 . July 2006 . 16865769 . 4087738 . 10.3748/wjg.v12.i27.4296 . dmy-all . free .
  42. Ferro A, Costa AR, Morais S, Bertuccio P, Rota M, Pelucchi C, Hu J, Johnson KC, Zhang ZF, Palli D, Ferraroni M, Yu GP, Bonzi R, Peleteiro B, López-Carrillo L, Tsugane S, Hamada GS, Hidaka A, Malekzadeh R, Zaridze D, Maximovich D, Vioque J, Navarrete-Muñoz EM, Alguacil J, Castaño-Vinyals G, Wolk A, Håkansson N, Hernández-Ramírez RU, Pakseresht M, Ward MH, Pourfarzi F, Mu L, López-Cervantes M, Persiani R, Kurtz RC, Lagiou A, Lagiou P, Boffetta P, Boccia S, Negri E, Camargo MC, Curado MP, La Vecchia C, Lunet N . Fruits and vegetables intake and gastric cancer risk: A pooled analysis within the Stomach cancer Pooling Project . Int J Cancer . 147 . 11 . 3090–3101 . December 2020 . 32525569 . 10.1002/ijc.33134 . 8545605 . 10216/143193 . free .
  43. Web site: What Are The Risk Factors For Stomach Cancer(Website). American Cancer Society. 31 March 2010. live. https://web.archive.org/web/20100706014402/http://www.cancer.org/Cancer/StomachCancer/DetailedGuide/stomach-cancer-risk-factors. 6 July 2010.
  44. Buckland G, Agudo A, Luján L, Jakszyn P, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Krogh V, Sacerdote C, Tumino R, Panico S, Nesi G, Manjer J, Regnér S, Johansson I, Stenling R, Sanchez MJ, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen NE, Key TJ, Bingham S, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Morois S, Boutron-Ruault MC, Trichopoulou A, Lagiou P, Trichopoulos D, Lund E, Couto E, Boffeta P, Jenab M, Riboli E, Romaguera D, Mouw T, González CA . Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study . The American Journal of Clinical Nutrition . 91 . 2 . 381–390 . February 2010 . 20007304 . 10.3945/ajcn.2009.28209 . free .
  45. Crew KD, Neugut AI . Epidemiology of gastric cancer . World Journal of Gastroenterology . 12 . 3 . 354–362 . January 2006 . 16489633 . 4066052 . 10.3748/wjg.v12.i3.354 . free .
  46. Hampel H, Abraham NS, El-Serag HB . Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications . Annals of Internal Medicine . 143 . 3 . 199–211 . August 2005 . 16061918 . 10.7326/0003-4819-143-3-200508020-00006 . 15540274 .
  47. Book: Josefssson M, Ekblad E . 2009 . 215–220. 22. Sodium Iodide Symporter (NIS) in Gastric Mucosa: Gastric Iodide Secretion . Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects . Preedy VR, Burrow GN, Watson R . 978-0-12-374135-6 . Elsevier.
  48. Venturi S . Evolutionary Significance of Iodine. Current Chemical Biology. 5. 2011. 3 . 155–162 . 1872-3136. 10.2174/187231311796765012.
  49. Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, Guidi A . Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach . Advances in Clinical Pathology . 4 . 1 . 11–17 . January 2000 . 10936894 .
  50. Web site: Hereditary Diffuse Cancer. No Stomach for Cancer. 21 October 2014. live. https://web.archive.org/web/20141020042257/http://www.nostomachforcancer.org/gastric-cancer/hereditary-diffuse-gastric-cancer. 20 October 2014.
  51. Kulmambetova G, Shtefanov I, Aitkulova A, Imanbekova M, Iskakova A, Makishev A, Ramankulov Y . Association of polymorphisms in TP53 and the promoter region of IL10 with gastric cancer in a Kazakh population . Bosnian Journal of Basic Medical Sciences . 20 . 4 . 539–546 . November 2020 . 32651972 . 7664782 . 10.17305/bjbms.2020.4761 .
  52. Web site: Gastric Cancer — Adenocarcinoma. International Cancer Genome Consortium. 24 February 2014. live. https://web.archive.org/web/20140421063815/http://icgc.org/icgc/cgp/69/509/70268. 21 April 2014.
  53. Web site: Gastric Cancer—Intestinal- and diffuse-type. International Cancer Genome Consortium. 24 February 2014. live. https://web.archive.org/web/20140207190902/http://icgc.org/icgc/cgp/69/371/811. 7 February 2014.
  54. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ, Seruca R, Gallinger S, Caldas C, Huntsman D . Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria . Journal of Medical Genetics . 41 . 7 . 508–517 . July 2004 . 15235021 . 1735838 . 10.1136/jmg.2004.018275 .
  55. Rahmani . Alireza . Khamutian . Samira . Doosti-Irani . Amin . Shokoohizadeh . Mohammad Javad . Shirmohammadi-Khorram . Nasrin . Sahraeei . Fatemeh . Khodabakhshi . Mahdi . Ahangaran . Nastaran . 2023-09-19 . The association of arsenic exposure with mortality due to cancer, diabetes, Alzheimer's and congenital anomalies using Poisson regression . Scientific Reports . en . 13 . 1 . 15456 . 10.1038/s41598-023-42744-4 . 37726351 . 2045-2322. 10509156 . 2023NatSR..1315456R .
  56. Tseng CH, Tseng FH . Diabetes and gastric cancer: the potential links . World Journal of Gastroenterology . 20 . 7 . 1701–1711 . February 2014 . 24587649 . 3930970 . 10.3748/wjg.v20.i7.1701 . free .
  57. Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O'Toole D, Reynolds JV . Gastric neuroendocrine tumours . Digestive Surgery . 29 . 4 . 331–348 . 2004 . 23075625 . 10.1159/000342988 . free .
  58. Kim J, Cheong JH, Chen J, Hyung WJ, Choi SH, Noh SH . Menetrier's disease in korea: report of two cases and review of cases in a gastric cancer prevalent region . Yonsei Medical Journal . 45 . 3 . 555–560 . June 2004 . 15227748 . 10.3349/ymj.2004.45.3.555 . free .
  59. Tsukamoto T, Mizoshita T, Tatematsu M . Gastric-and-intestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization . Gastric Cancer . 9 . 3 . 156–166 . 2006 . 16952033 . 10.1007/s10120-006-0375-6 . free .
  60. Ezzeddini R, Somi MH, Taghikhani M, Moaddab SY, Masnadi Shirazi K, Shirmohammadi M, Eftekharsadat AT, Sadighi Moghaddam B, Salek Farrokhi A . Association of Foxp3 rs3761548 polymorphism with cytokines concentration in gastric adenocarcinoma patients . Cytokine . 138 . 155351 . February 2021 . 33127257 . 10.1016/j.cyto.2020.155351 . 226218796 .
  61. Li D, Zhang J, Yao WZ, Zhang DL, Feng CC, He Q, Lv HH, Cao YP, Wang J, Qi Y, Wu SR, Wang N, Zhao J, Shi YQ . The relationship between gastric cancer, its precancerous lesions and bile reflux: A retrospective study . J Dig Dis . 21 . 4 . 222–229 . April 2020 . 32187838 . 7317534 . 10.1111/1751-2980.12858 .
  62. Web site: Gastric Cancer. The Lecturio Medical Concept Library . 22 July 2021.
  63. Virmani V, Khandelwal A, Sethi V, Fraser-Hill M, Fasih N, Kielar A . Neoplastic stomach lesions and their mimickers: spectrum of imaging manifestations . Cancer Imaging . 12 . 269–278 . August 2012 . 1 . 22935192 . 3458788 . 10.1102/1470-7330.2012.0031 .
  64. Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, Song Q, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD, Leja M, Haick H . A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions . British Journal of Cancer . 108 . 4 . 941–950 . March 2013 . 23462808 . 3590679 . 10.1038/bjc.2013.44 .
  65. Web site: Breath Test Could Detect And Diagnose Stomach Cancer. 6 March 2013. 11 March 2022. Medical News Today. Paddock C .
  66. Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Haick H . Detection of precancerous gastric lesions and gastric cancer through exhaled breath . Gut . 65 . 3 . 400–407 . March 2016 . 25869737 . 10.1136/gutjnl-2014-308536 . 206961387 .
  67. Wang L, Li J, Xiong X, Hao T, Zhang C, Gao Z, Zhong L, Zhao Y . Volatile organic compounds as a potential screening tool for neoplasm of the digestive system: a meta-analysis . Scientific Reports . 11 . 1 . 23716 . December 2021 . 34887450 . 8660806 . 10.1038/s41598-021-02906-8 . 2021NatSR..1123716W .
  68. Inoue H, Kudo SE, Shiokawa A . Technology insight: Laser-scanning confocal microscopy and endocytoscopy for cellular observation of the gastrointestinal tract . Nature Clinical Practice. Gastroenterology & Hepatology . 2 . 1 . 31–37 . January 2005 . 16265098 . 10.1038/ncpgasthep0072 . 34445155 .
  69. Pentenero M, Carrozzo M, Pagano M, Gandolfo S . Oral acanthosis nigricans, tripe palms and sign of leser-trélat in a patient with gastric adenocarcinoma . International Journal of Dermatology . 43 . 7 . 530–532 . July 2004 . 15230897 . 10.1111/j.1365-4632.2004.02159.x . 37434568 .
  70. Beg M, Singh M, Saraswat MK, Rewari BB . 2002 . Occult Gastrointestinal Bleeding: Detection, Interpretation, and Evaluation . JIACM . 3 . 2 . 153–58 . live . https://web.archive.org/web/20101122112908/http://medind.nic.in/jac/t02/i2/jact02i2p153.pdf . 22 November 2010 .
  71. Book: Robbins SL, Cotran RS, Kuma V . Pathologic Basis of Disease . 8th . 784 . Saunders Elsevier . 2010 . 978-1-4160-3121-5 .
  72. Burkitt MD, Duckworth CA, Williams JM, Pritchard DM . Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models . Disease Models & Mechanisms . 10 . 2 . 89–104 . February 2017 . 28151409 . 5312008 . 10.1242/dmm.027649 .
  73. Qu Q, Xuan W, Fan GH . Roles of resolvins in the resolution of acute inflammation . Cell Biology International . 39 . 1 . 3–22 . January 2015 . 25052386 . 10.1002/cbin.10345 . 10160642 .
  74. Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW . CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy . Radiographics . 26 . 1 . 143–156 . 2006 . 16418249 . 10.1148/rg.261055078 .
  75. Web site: Detailed Guide: Stomach Cancer Treatment Choices by Type and Stage of Stomach Cancer. 3 November 2009. American Cancer Society. live. https://web.archive.org/web/20091008105442/http://www.cancer.org/docroot/cri/content/cri_2_4_4x_treatment_choices_by_type_and_stage_of_stomach_cancer_40.asp. 8 October 2009.
  76. Web site: What Are The Stages Of Stomach Cancer?. Slowik G . October 2009. ehealthmd.com. live. https://web.archive.org/web/20100102013902/http://ehealthmd.com/library/stomachcancer/STC_stages.html. 2 January 2010.
  77. Web site: Detailed Guide: Stomach Cancer: How Is Stomach Cancer Staged?. American Cancer Society. live. https://web.archive.org/web/20080325104115/http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_stomach_cancer_staged_40.asp. 25 March 2008.
  78. Paterson HM, McCole D, Auld CD . Impact of open-access endoscopy on detection of early oesophageal and gastric cancer 1994 - 2003: population-based study . Endoscopy . 38 . 5 . 503–507 . May 2006 . 16767587 . 10.1055/s-2006-925124 . 31841360 .
  79. Crane SJ, Locke GR, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ . Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study . Mayo Clinic Proceedings . 83 . 10 . 1087–1094 . October 2008 . 18828967 . 2597541 . 10.4065/83.10.1087 .
  80. Heise K, Bertran E, Andia ME, Ferreccio C . Incidence and survival of stomach cancer in a high-risk population of Chile . World Journal of Gastroenterology . 15 . 15 . 1854–1862 . April 2009 . 19370783 . 2670413 . 10.3748/wjg.15.1854 . free .
  81. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P . Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials . BMJ . 348 . g3174 . May 2014 . 24846275 . 4027797 . 10.1136/bmj.g3174 .
  82. Woo HD, Park S, Oh K, Kim HJ, Shin HR, Moon HK, Kim J . Diet and cancer risk in the Korean population: a meta- analysis . Asian Pacific Journal of Cancer Prevention . 15 . 19 . 8509–8519 . 2014 . 25339056 . 10.7314/apjcp.2014.15.19.8509 . dmy-all . free .
  83. Kong P, Cai Q, Geng Q, Wang J, Lan Y, Zhan Y, Xu D . Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies . PLOS ONE . 9 . 12 . e116060 . 2014 . 25549091 . 4280145 . 10.1371/journal.pone.0116060 . free . 2014PLoSO...9k6060K .
  84. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C . Antioxidant supplements for preventing gastrointestinal cancers . The Cochrane Database of Systematic Reviews . 3 . CD004183 . July 2008 . 18677777 . 10.1002/14651858.CD004183.pub3 .
  85. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C . Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases . The Cochrane Database of Systematic Reviews . 2012 . 3 . CD007176 . March 2012 . 22419320 . 8407395 . 10.1002/14651858.CD007176.pub2 . free . Submitted manuscript . 10138/136201 .
  86. Aziz S, Rasheed F, Zahra R, König S . Gastric Cancer Pre-Stage Detection and Early Diagnosis of Gastritis Using Serum Protein Signatures . Molecules . 27 . 9 . 2857 . April 2022 . 35566209 . 9099457 . 10.3390/molecules27092857 . free .
  87. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA . Modern oncological approaches to gastric adenocarcinoma . Gastroenterology Clinics of North America . 42 . 2 . 359–369 . June 2013 . 23639645 . 10.1016/j.gtc.2013.01.011 .
  88. Chen K, Xu XW, Zhang RC, Pan Y, Wu D, Mou YP . Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer . World Journal of Gastroenterology . 19 . 32 . 5365–5376 . August 2013 . 23983442 . 3752573 . 10.3748/wjg.v19.i32.5365 . free .
  89. Pretz JL, Wo JY, Mamon HJ, Kachnic LA, Hong TS . Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer . Surgical Oncology Clinics of North America . 22 . 3 . 511–524 . July 2013 . 23622077 . 10.1016/j.soc.2013.02.005 .
  90. Meza-Junco J, Au HJ, Sawyer MB . Critical appraisal of trastuzumab in treatment of advanced stomach cancer . Cancer Management and Research . 3 . 57–64 . March 2011 . 21556317 . 3085240 . 10.2147/CMAR.S12698 . free .
  91. Best LM, Mughal M, Gurusamy KS . Laparoscopic versus open gastrectomy for gastric cancer . The Cochrane Database of Systematic Reviews . 2016 . 3 . CD011389 . March 2016 . 27030300 . 6769173 . 10.1002/14651858.CD011389.pub2 .
  92. Pouch Versus No Pouch Following Total gastrectomy: Meta-analysis of Randomized and Non-randomized Studies . Annals of Surgery . 269 . 6 . 1041–1053 . December 2018 . 30571657 . 10.1097/sla.0000000000003082 . 58584460 . Syn NL, Wee I, Shabbir A, Kim G, So JB .
  93. Narayan . Raja . Kim . Jane . Park . Do Joong . Robotic-assisted proximal gastrectomy with a laparoscopic-assisted double-tract reconstruction for proximal early gastric cancer . J Med Insight . 2024 . 2024 . 427 . 10.24296/jomi/427.
  94. Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, Zhou B, Xu H . Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis . BMC Cancer . 13 . 1 . 577 . December 2013 . 24304886 . 4235220 . 10.1186/1471-2407-13-577 . live . dmy-all . https://web.archive.org/web/20140407074334/http://www.biomedcentral.com/content/pdf/1471-2407-13-577.pdf . 7 April 2014 . free .
  95. Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, Cascinu S . Chemotherapy for advanced gastric cancer: across the years for a standard of care . Expert Opinion on Pharmacotherapy . 8 . 6 . 797–808 . April 2007 . 17425475 . 10.1517/14656566.8.6.797 . 24196381 .
  96. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Di Nuovo F, Romagnoli S, Bosari S . HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions . Modern Pathology . 26 . 6 . 816–824 . June 2013 . 23348899 . 10.1038/modpathol.2012.228 . dmy-all . free .
  97. Web site: The stomach cancer proteome – The Human Protein Atlas. www.proteinatlas.org.
  98. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F . A pathology atlas of the human cancer transcriptome . Science . 357 . 6352 . eaan2507 . August 2017 . 28818916 . 10.1126/science.aan2507 . free .
  99. Calik I, Calik M, Sarikaya B, Ozercan IH, Arslan R, Artas G, Dagli AF . P2X7 receptor as an independent prognostic indicator in gastric cancer . Bosnian Journal of Basic Medical Sciences . 20 . 2 . 188–196 . May 2020 . 32070268 . 7202194 . 10.17305/bjbms.2020.4620 .
  100. Book: WHO report on cancer: setting priorities, investing wisely and providing care for all. . World Health Organization (WHO) . 2020 . 978-92-4-000129-9 . p. 26 . English.
  101. Parkin DM, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002 . CA: A Cancer Journal for Clinicians. 55 . 2 . 74–108 . 2005 . 15761078 . 10.3322/canjclin.55.2.74 . 13746942 . free .
  102. Web site: Are the number of cancer cases increasing or decreasing in the world? . 1 April 2008 . WHO Online Q&A . WHO . 11 May 2009 . dead . https://web.archive.org/web/20090514012915/http://www.who.int/features/qa/15/en/index.html . 14 May 2009 .
  103. Book: . 2014 .
  104. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, etal . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 . Lancet . 380 . 9859 . 2095–2128 . December 2012 . 23245604 . 10.1016/S0140-6736(12)61728-0 . 10790329 . free . 1541253 . 10536/DRO/DU:30050819 .
  105. Web site: PRESS RELEASE N° 224 Global battle against cancer won't be won with treatment alone: Effective prevention measures urgently needed to prevent cancer crisis. World Health Organization. 14 March 2014 . 3 February 2014 . live . https://web.archive.org/web/20140303133031/http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf . 3 March 2014.
  106. Mauad EC, Nogueira JL, Souza JM, Wohnrath DR, Oliveira AT, Colli G, Colli AM . Gastric Cancer in Young Adults . Câncer gástrico em adultos jovens . Rev. Bras. Cancerol. . 46 . 3 . 299–304 . 2000 . 10.32635/2176-9745.RBC.2000v46n3.2441 . 179189212 . live . https://web.archive.org/web/20090703104120/http://www.inca.gov.br/rbc/n_46/v03/english/article6.html . 3 July 2009 . free .
  107. Web site: Health profile: United States. Le Duc Media. 31 January 2016. live. https://web.archive.org/web/20160114181325/http://www.worldlifeexpectancy.com/country-health-profile/united-states. 14 January 2016.
  108. Web site: Health profile: China. Le Duc Media. 31 January 2016. live. https://web.archive.org/web/20160103182525/http://www.worldlifeexpectancy.com/country-health-profile/china. 3 January 2016.
  109. Web site: Stomach Cancer: Death Rate Per 100,000. Le Duc Media. 13 March 2014. live. https://web.archive.org/web/20140913035347/http://www.worldlifeexpectancy.com/cause-of-death/stomach-cancer/by-country/. 13 September 2014.
  110. Web site: Stomach cancer statistics. Cancer Research UK. 28 October 2014. live. https://web.archive.org/web/20141007170251/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/stomach/. 7 October 2014.
  111. Asombang AW, Rahman R, Ibdah JA . Gastric cancer in Africa: current management and outcomes . World Journal of Gastroenterology . 20 . 14 . 3875–3879 . April 2014 . 24833842 . 3983443 . 10.3748/wjg.v20.i14.3875 . free .
  112. Louw JA, Kidd MS, Kummer AF, Taylor K, Kotze U, Hanslo D . The relationship between Helicobacter pylori infection, the virulence genotypes of the infecting strain and gastric cancer in the African setting . Helicobacter . 6 . 4 . 268–273 . December 2001 . 11843958 . 10.1046/j.1523-5378.2001.00044.x . 25990463 .
  113. Book: Withrow SJ . 22 Cancer of the Gastrointestinal tract § E: Gastric Cancer: Diagnostic Techniques and Work-Up . https://books.google.com/books?id=nYYlauGf0D4C&pg=PA402 . Vail DM . Withrow and MacEwen's Small Animal Clinical Oncology . Elsevier . 5th . 2013 . 978-0-323-24197-7 . 402–3 .
  114. Alizadeh M, Raufman JP . Gastrointestinal neoplasia: carcinogenic interaction between bile acids and Helicobacter pylori in the stomach . The Journal of Clinical Investigation . 132 . 10 . May 2022 . 35575088 . 9106340 . 10.1172/JCI160194 .
  115. Noto JM, Piazuelo MB, Shah SC, Romero-Gallo J, Hart JL, Di C, Carmichael JD, Delgado AG, Halvorson AE, Greevy RA, Wroblewski LE, Sharma A, Newton AB, Allaman MM, Wilson KT, Washington MK, Calcutt MW, Schey KL, Cummings BP, Flynn CR, Zackular JP, Peek RM . Iron deficiency linked to altered bile acid metabolism promotes Helicobacter pylori-induced inflammation-driven gastric carcinogenesis . The Journal of Clinical Investigation . 132 . 10 . May 2022 . 35316215 . 9106351 . 10.1172/JCI147822 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Stomach cancer".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.